Early-stage life science companies do not fail because the science is weak. They fail because the science never becomes investable. Across therapeutics, devices, diagnostics, and digital health, failure rates approach ninety percent. The default explanation is technical risk. The data did not hold. The biology did not translate. The product did not perform. That is not what usually happens. What happens is structural. Companies are built without a system for converting discovery into something capital can evaluate, compare, and act on. They generate data before defining the problem. They raise capital before removing uncertainty. They move forward without knowing what the next decision-maker needs to see. Capital does not fund ideas. It funds signal.
Signal is what allows an investor or partner to act with confidence. It is produced when specific forms of uncertainty are systematically removed. Without signal, even strong science remains interesting but unfundable. With it, capital moves. Over the next six articles, we will break down how that signal is created. Not through storytelling, but through the systematic reduction of risk across a defined stack. Each layer represents a different barrier to action. Each must be addressed in sequence. Investability emerges when enough of this stack has been reduced to a level that supports a decision.
- The Problem Is Not the Science: A Seven-Part Series on De-Risking, Signal, and Investability
- Technical Risk – From Belief to Evidence
- From Proof to Approval: Regulatory Risk
- From Plan to Progress: Execution Risk
- From Progress to Viability: Economic Risk
- From Viability to Capital: Financing Risk
- From Story to Outcome: Exit Risk
Next Phase Newsletter 